Delving into the Latest Updates on Kaigen Pharma Co., Ltd. with Synapse

Overview

Tags

Other Diseases

Digestive System Disorders

Otorhinolaryngologic Diseases

Small molecule drug

Contrast agent

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	4
Contrast agent	1

Top 5 Target	Count

mAChRs(Muscarinic acetylcholine receptor)	1

Evaluation of the anti-glycation effect and skin protection effect by a supplement containing brown algae extract powder. (A randomized,Double-blind,Placebo-controlled, Parallel group study) - Evaluation of the anti-glycation effect and skin protection effect by a supplement containing brown algae extract powder.

Start Date14 Jun 2021

Sponsor / Collaborator

Kaigen Pharma Co., Ltd.

JPRN-UMIN000000772 / CompletedNot Applicable

Randomization of Sodium Alginate and Mosapride Citrate for Patients with Gastroesophageal Reflux Disease (GERD) Following Distal Gastrectomy with Billroth I Reconstruction - A Multicenter Comparative Study - Randomization of Sodium Alginate and Mosapride Citrate for Patients with Gastroesophageal Reflux Disease (GERD) Following Distal Gastrectomy with Billroth I Reconstruction - A Multicenter Comparative Study

Start Date01 Oct 2006

Sponsor / Collaborator

Kyosei Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Kaigen Pharma Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Kaigen Pharma Co., Ltd.

Login to view more data

15

Literatures (Medical) associated with Kaigen Pharma Co., Ltd.

01 Apr 2024·International Journal of Biological Macromolecules

Swelling behavior of calcium ion-crosslinked sodium alginate in an in vitro hemostatic tamponade model

Article

Author: Sugawara, Hideto ; Maehara, Shinya ; Suzuki, Sayaka ; Nishida, Ryuichi ; Yamauchi, Kousuke ; Yamamoto, Junji ; Yoshihara, Takahiro ; Nakajima, Kiyokazu ; Sato, Masahiro ; Azuma, Tsutomu

Various types of hemostatic agents are used to manage bleeding in surgery. Many such agents are animal products, which carry the risk of secondary infection. The aim of this study is to develop a novel hemostatic agent from a non-animal source that quickly stops bleeding, is easy to use, and has no risk of infection. In this study, we synthesized calcium ion-crosslinked sodium alginate (Alg-Na/Ca) by partial substitution of Ca ions for Na ions in sodium alginate. We prepared 12 kinds of Alg-Na/Ca powders with different Ca mass ratios, molecular weights, M/G ratios and particle size distributions and measured their swelling ratio and the burst pressure generated. We found that Alg-Na/Ca began to swell immediately after contact with saline, especially Alg-Na/Ca at Ca mass ratios of 74.1-77.0 % showed a high swelling ratio after 2 min and a high burst pressure, over 200 % and 500 mmHg respectively. Also, there is a correlation between the swelling ratio after 2 min and the burst pressure. Our results suggest that, by optimizing the composition conditions, Alg-Na/Ca may be an effective hemostatic agent that could act as a tamponade by absorbing and swelling at a bleeding site to quickly achieve primary hemostasis.

01 Dec 2023·Surgery

Randomized controlled trial of new hemostatic material “sodium calcium alginate” in a preclinical model

Article

Author: Kubo, Yuto ; Nishida, Ryuichi ; Yamamoto, Junji ; Tanaka, Koji ; Yamashita, Kotaro ; Yamamoto, Kazuyoshi ; Suzuki, Sayaka ; Yoshihara, Takahiro ; Nakajima, Kiyokazu ; Kurokawa, Yukinori ; Doki, Yuichiro ; Satoh, Masahiro ; Takahashi, Tsuyoshi ; Makino, Tomoki ; Eguchi, Hidetoshi ; Saito, Takuro

BACKGROUNDThe demand for nonbiological hemostatic materials has increased in surgical practice; however, few have sufficient hemostatic efficacy. This study investigated whether optimizing the composition of sodium calcium alginate, which forms a stable gel, improves hemostatic efficacy.METHODSThe sodium calcium alginate was changed for each composition, including powder size, calcium substitution rate, molecular weight, and mannuronic/guluronic acid ratio. The hemostasis in liver punch-out injury and bleeding was evaluated using swine. For the study, sodium calcium alginate with different compositions was randomly applied to bleeding sites. Previous hemostatic materials, including cellulose and sodium alginate, were used as a control. We investigated hemostasis at 2 and 5 minutes after application.RESULTSEach powder size (53-150 μm, 150-250 μm, 53-250 μm) had a similar hemostatic effect. However, the hemostatic rate was significantly higher in sodium calcium alginate than in previous hemostatic materials (P value < .01). A 74.1% calcium substitution rate had the highest hemostasis at 2 and 5 minutes after application (2 minutes: 100%, 5 minutes: 95.2%). Regarding molecular weight, the hemostatic rate was significantly higher in 333,000 than in 50,000 (2 minutes: 95% vs 70%, 5 minutes: 95% vs 70%, P = .038). Moreover, a 1.9 mannuronic/guluronic acid ratio had the highest hemostasis compared with the 0.4 mannuronic/guluronic acid ratio (2 minutes: 58.8% vs 11.8%, 5 minutes: 58.8% vs 0%, P = .033) CONCLUSION: The composition of sodium calcium alginate with a high hemostatic effect was optimized. This new hemostatic material demonstrated potential usefulness for bleeding during surgery.

01 Jan 2022·Proceedings for Annual Meeting of The Japanese Pharmacological Society

Evaluation of the anti-glycation effect and skin protection effect by a supplement containing brown algae extract powder. (A randomized,Double-blind,Placebo-controlled, Parallel group study)

Author: Yamamoto, Junji ; Takebe, Naoto ; Azuma, Mitsuhiro ; Matsumoto, Toshihiko ; Yamauchi, Kousuke

100 Deals associated with Kaigen Pharma Co., Ltd.

Login to view more data

100 Translational Medicine associated with Kaigen Pharma Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Barium Sulfate	Contrast agents More	Approved
Polidocanol ( mAChRs )	primary varicose veins More	Approved
Sodium bicarbonate/tartaric acid	Contrast agents More	Approved
Sodium Alginate	Duodenal Ulcer More	Approved